Erythropoietin
- Generic Name
- Erythropoietin
- Brand Names
- Procrit, Eprex, Epprex, Epoetin Alfa Hexal, Silapo, Biopoin, Abseamed, Eporatio, NeoRecormon, Epogen, Retacrit
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 11096-26-7
- Unique Ingredient Identifier
- 64FS3BFH5W
- Background
Erythropoietin (EPO) is a growth factor produced in the kidneys that stimulates the production of red blood cells. It works by promoting the division and differentiation of committed erythroid progenitors in the bone marrow . Epoetin alfa (Epoge) was developed by Amgen Inc. in 1983 as the first rhEPO commercialized in the United States, followed by other alf...
- Indication
用于肾功能不全合并的贫血，艾滋病本身或因治疗引起的贫血，恶性肿瘤伴发的贫血及风湿性贫血等。另外，为择期手术储存自体血而反复采血的患者，同时应用本品可预防发生贫血。
- Associated Conditions
- Anemia, Blood Loss During Surgery, Anemia caused by Zidovudine
- Associated Therapies
- -
Exosome Proteomics to Detect EPO
- First Posted Date
- 2018-10-09
- Last Posted Date
- 2019-09-25
- Lead Sponsor
- Morten Hostrup, PhD
- Target Recruit Count
- 72
- Registration Number
- NCT03700515
- Locations
- 🇩🇰
August Krogh Building, Copenhagen, Denmark
Predictors of Response to Iron and Erythropoietin Stimulating Agents
- Conditions
- Interventions
- First Posted Date
- 2018-09-05
- Last Posted Date
- 2019-07-05
- Lead Sponsor
- Imperial College London
- Target Recruit Count
- 197
- Registration Number
- NCT03658876
Biological Predictive Factors of Response to ESA in Low Risk MDS Patients
- First Posted Date
- 2018-07-26
- Last Posted Date
- 2018-07-26
- Target Recruit Count
- 70
- Registration Number
- NCT03598582
Pharmacokinetics and Pharmacodynamics Assessment of Drug Eritromax Compared to Eprex in Healthy Subjects.
- First Posted Date
- 2018-06-28
- Last Posted Date
- 2022-11-03
- Lead Sponsor
- Azidus Brasil
- Target Recruit Count
- 40
- Registration Number
- NCT03572647
- Locations
- 🇧🇷
LAL Clínica Pesquisa e Desenvolvimento Ltda., Valinhos, São Paulo, Brazil
To Evaluate the Efficacy, Safety, and Immunogenicity of Subcutaneous Eporon Versus Epoetin Alfa (Eprex)
- First Posted Date
- 2018-05-11
- Last Posted Date
- 2019-12-10
- Lead Sponsor
- Dong-A ST Co., Ltd.
- Target Recruit Count
- 214
- Registration Number
- NCT03521713
- Locations
- 🇹🇷
Gazi University Medical Faculty, Ankara, Turkey
Erythropoietin Role in Acute Kidney Injury
- First Posted Date
- 2018-01-17
- Last Posted Date
- 2021-12-28
- Lead Sponsor
- Saint-Joseph University
- Target Recruit Count
- 134
- Registration Number
- NCT03401710
- Locations
- 🇱🇧
Saint Georges Hospital, Aajaltoûn, Ajaltoun, Lebanon
Effects of Erythropoietin for Cognitive Side-effects of ECT
- Conditions
- Interventions
- First Posted Date
- 2017-11-13
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Martin Balslev Jørgensen
- Target Recruit Count
- 60
- Registration Number
- NCT03339596
- Locations
- 🇩🇰
Mental Health Services, Capital Region of Denmark, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Copenhagen O, Denmark
Effects of Erythropoietin on Cognition and Neural Activity in Mood Disorders
- Conditions
- Interventions
- First Posted Date
- 2017-10-20
- Last Posted Date
- 2023-03-16
- Lead Sponsor
- Lars Vedel Kessing
- Target Recruit Count
- 103
- Registration Number
- NCT03315897
- Locations
- 🇩🇰
Mental Health Services, Capital Region of Denmark, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
Evaluation of Erythroferrone as a New Biomarker of Erythropoesis Stimulating Agents
- First Posted Date
- 2017-09-08
- Last Posted Date
- 2017-09-08
- Lead Sponsor
- Association Athletes For Transparency
- Target Recruit Count
- 24
- Registration Number
- NCT03276910
A Trial Testing Early vs Late Onset of EPO Alfa Treatment in Lower Risk MDS
- First Posted Date
- 2017-07-21
- Last Posted Date
- 2020-12-02
- Lead Sponsor
- Groupe Francophone des Myelodysplasies
- Target Recruit Count
- 124
- Registration Number
- NCT03223961
- Locations
- 🇫🇷
Chu Amiens, Amiens, France
🇫🇷CH Avignon, Avignon, France
🇫🇷CH Angers, Angers, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.